Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response
Elisa C. Toffoli(Amsterdam University Medical Centers), Tanja D. de Gruijl(Dutch Cancer Society), Abdolkarim Sheikhi(Dezful University of Medical Sciences), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Henk M.W. Verheul(Erasmus MC Cancer Institute), Yannick D. Höppner(Amsterdam University Medical Centers), Pita de Kok(Amsterdam University Medical Centers), Mahsa Yazdanpanah‐Samani(Shiraz University of Medical Sciences)
Cited by 41
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
|Nature reviews. Cancer|2007|502